Takeda Pharmaceutical Li... (TAK)
Takeda Pharmaceutical Statistics
Share Statistics
Takeda Pharmaceutical has 3.17B shares outstanding. The number of shares has increased by 1.04% in one year.
| Shares Outstanding | 3.17B |
| Shares Change (YoY) | 1.04% |
| Shares Change (QoQ) | 0.48% |
| Owned by Institutions (%) | 4.55% |
| Shares Floating | 3.17B |
| Failed to Deliver (FTD) Shares | 90 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 3.71M, so 0.12% of the outstanding shares have been sold short.
| Short Interest | 3.71M |
| Short % of Shares Out | 0.12% |
| Short % of Float | 0.12% |
| Short Ratio (days to cover) | 2.08 |
Valuation Ratios
The PE ratio is 45.16 and the forward PE ratio is 25.27. Takeda Pharmaceutical's PEG ratio is -0.82.
| PE Ratio | 45.16 |
| Forward PE | 25.27 |
| PS Ratio | 1.53 |
| Forward PS | 0 |
| PB Ratio | 0.89 |
| P/FCF Ratio | 27.62 |
| PEG Ratio | -0.82 |
Enterprise Valuation
Takeda Pharmaceutical Limited has an Enterprise Value (EV) of 7,255.3B.
| EV / Earnings | 50.36 |
| EV / Sales | 1.7 |
| EV / EBITDA | 8.3 |
| EV / EBIT | 33.89 |
| EV / FCF | 30.79 |
Financial Position
The company has a current ratio of 1.11, with a Debt / Equity ratio of 0.67.
| Current Ratio | 1.11 |
| Quick Ratio | 0.58 |
| Debt / Equity | 0.67 |
| Total Debt / Capitalization | 39.97 |
| Cash Flow / Debt | 0.15 |
| Interest Coverage | 1.39 |
Financial Efficiency
Return on equity (ROE) is 0.02% and return on capital (ROIC) is 4.83%.
| Return on Equity (ROE) | 0.02% |
| Return on Assets (ROA) | 0.01% |
| Return on Capital (ROIC) | 4.83% |
| Revenue Per Employee | $86,519,388.81 |
| Profits Per Employee | $2,923,378.18 |
| Employee Count | 49,281 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 1.18 |
Taxes
| Income Tax | -91.41B |
| Effective Tax Rate | -1.73 |
Stock Price Statistics
The stock price has increased by 9% in the last 52 weeks. The beta is 0.41, so Takeda Pharmaceutical's price volatility has been higher than the market average.
| Beta | 0.41 |
| 52-Week Price Change | 9% |
| 50-Day Moving Average | 14.11 |
| 200-Day Moving Average | 13.9 |
| Relative Strength Index (RSI) | 65.78 |
| Average Volume (20 Days) | 1.76M |
Income Statement
In the last 12 months, Takeda Pharmaceutical had revenue of 4,263.8B and earned 144.07B in profits. Earnings per share was 92.09.
| Revenue | 4,263.8B |
| Gross Profit | 2,832.3B |
| Operating Income | 214.07B |
| Net Income | 144.07B |
| EBITDA | 874.6B |
| EBIT | 214.07B |
| Earnings Per Share (EPS) | 92.09 |
Balance Sheet
The company has 457.8B in cash and 4,843.8B in debt, giving a net cash position of -4,386B.
| Cash & Cash Equivalents | 457.8B |
| Total Debt | 4,843.8B |
| Net Cash | -4,386B |
| Retained Earnings | 1,391.2B |
| Total Assets | 14,573B |
| Working Capital | 666.78B |
Cash Flow
In the last 12 months, operating cash flow was 716.34B and capital expenditures -480.73B, giving a free cash flow of 235.61B.
| Operating Cash Flow | 716.34B |
| Capital Expenditures | -480.73B |
| Free Cash Flow | 235.61B |
| FCF Per Share | 150.61 |
Margins
Gross margin is 66.43%, with operating and profit margins of 5.02% and 3.38%.
| Gross Margin | 66.43% |
| Operating Margin | 5.02% |
| Pretax Margin | 1.24% |
| Profit Margin | 3.38% |
| EBITDA Margin | 20.51% |
| EBIT Margin | 5.02% |
| FCF Margin | 5.53% |
Dividends & Yields
TAK pays an annual dividend of $0.51, which amounts to a dividend yield of 3.59%.
| Dividend Per Share | $0.51 |
| Dividend Yield | 3.59% |
| Dividend Growth (YoY) | -4% |
| Payout Ratio | 118.6% |
| Earnings Yield | 608.26% |
| FCF Yield | 490.74% |
Analyst Forecast
Currently there are no analyst rating for TAK.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 0.62 |
| Piotroski F-Score | 6 |